1. Home
  2. NCMI vs TNXP Comparison

NCMI vs TNXP Comparison

Compare NCMI & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo National CineMedia Inc.

NCMI

National CineMedia Inc.

HOLD

Current Price

$2.46

Market Cap

244.6M

ML Signal

HOLD

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

N/A

Current Price

$13.19

Market Cap

199.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NCMI
TNXP
Founded
2005
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
244.6M
199.7M
IPO Year
2006
2008

Fundamental Metrics

Financial Performance
Metric
NCMI
TNXP
Price
$2.46
$13.19
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$5.63
N/A
AVG Volume (30 Days)
1.6M
490.5K
Earning Date
05-05-2026
05-11-2026
Dividend Yield
3.36%
N/A
EPS Growth
52.17
91.75
EPS
N/A
N/A
Revenue
N/A
$13,107,000.00
Revenue This Year
$11.20
$558.11
Revenue Next Year
$6.22
$38.29
P/E Ratio
N/A
N/A
Revenue Growth
N/A
29.85
52 Week Low
$2.16
$9.40
52 Week High
$5.03
$29.19

Technical Indicators

Market Signals
Indicator
NCMI
TNXP
Relative Strength Index (RSI) 34.71 55.91
Support Level $2.16 $13.13
Resistance Level $3.74 $14.30
Average True Range (ATR) 0.12 0.68
MACD 0.02 -0.04
Stochastic Oscillator 18.39 43.11

Price Performance

Historical Comparison
NCMI
TNXP

About NCMI National CineMedia Inc.

National CineMedia Inc is a cinema advertising platform in the U.S. It derives revenue from the sale of advertising to national, regional and local businesses through The Noovie Show and the CineLife Show, the cinema advertising and entertainment show seen on movie screens across the U.S., on LEN, a series of strategically-placed screens located in movie theater lobbies, as well as other forms of advertising and promotions in theater lobbies.

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

Share on Social Networks: